- CA$33.15m
- CA$28.33m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.82 | ||
Price to Tang. Book | 3.05 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -184.29% | ||
Return on Equity | -83.28% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 0.19 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.
Directors
- Zeeshan Saeed CCH
- Anthony Durkacz CCH (39)
- Nathan Coyle CFO
- Sara May CEX
- Huma Qamar SVP
- Sandra Lottes VPR
- Edward Brennan OTH
- Shahzad Shah OTH
- Donal Carroll DRC
- Fernando Cugliari DRC
- Nitin Kaushal DRC
- Lawrence Latowsky DRC
- Adnan Bashir IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 1st, 1998
- Public Since
- May 29th, 2018
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 40,429,641
- Address
- First Canadian Place, TORONTO, M5X 1A4
- Web
- https://www.fsdpharma.com/
- Phone
- +1 4168548884
- Auditors
- MNP LLP
Upcoming Events for HUGE
FSD Pharma Inc Annual Shareholders Meeting
Q2 2024 FSD Pharma Inc Earnings Release
Similar to HUGE
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
FAQ
As of Today at 19:08 UTC, shares in FSD Pharma are trading at CA$0.82. This share price information is delayed by 15 minutes.
Shares in FSD Pharma last closed at CA$0.82 and the price had moved by -69.17% over the past 365 days. In terms of relative price strength the FSD Pharma share price has underperformed the Toronto Stock Exchange 300 Composite Index by -71.03% over the past year.
The overall consensus recommendation for FSD Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
FSD Pharma does not currently pay a dividend.
FSD Pharma does not currently pay a dividend.
FSD Pharma does not currently pay a dividend.
To buy shares in FSD Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.82, shares in FSD Pharma had a market capitalisation of CA$33.15m.
Here are the trading details for FSD Pharma:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: HUGE
Based on an overall assessment of its quality, value and momentum FSD Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like FSD Pharma. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -54.08%.
As of the last closing price of CA$0.82, shares in FSD Pharma were trading -41.93% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The FSD Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.82.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
FSD Pharma's management team is headed by:
- Zeeshan Saeed - CCH
- Anthony Durkacz - CCH
- Nathan Coyle - CFO
- Sara May - CEX
- Huma Qamar - SVP
- Sandra Lottes - VPR
- Edward Brennan - OTH
- Shahzad Shah - OTH
- Donal Carroll - DRC
- Fernando Cugliari - DRC
- Nitin Kaushal - DRC
- Lawrence Latowsky - DRC
- Adnan Bashir - IND